重大事件
即時報告
8-K
2026-06-16
Silence Therapeutics plc 於 2026 年 6 月 16 日舉行年度股東大會（AGM），會上九項決議案全部獲得通過。主要結果如下：
AI 繁中摘要
Silence Therapeutics plc 於 2026 年 6 月 16 日舉行年度股東大會（AGM），會上九項決議案全部獲得通過。主要結果如下：
- 重新選舉 Rhonda Hellums 為董事：贊成 47,160,731 票，反對 5,557,090 票，棄權 4,680 票。
- 重新選舉 James Ede-Golightly 為董事：贊成 52,112,045 票，反對 605,683 票，棄權 4,680 票。
- 諮詢性通過高層管理人員薪酬：贊成 48,234,208 票，反對 73,667 票，棄權 4,414,536 票。
- 批准委任 PricewaterhouseCoopers LLP 為美國獨立註冊會計師事務所（2026 年度）：贊成 52,718,407 票，反對 2,885 票，棄權 1,119 票。
- 重新委任 PricewaterhouseCoopers LLP 為英國法定核數師：贊成 52,718,407 票，反對 2,885 票，棄權 1,119 票。
- 授權審計及風險委員會釐定英國核數師酬金（2026 年度）：贊成 52,714,237 票，反對 6,155 票，棄權 1,869 票。
- 接收及採納 2025 年英國法定年度賬目及報告：贊成 52,715,076 票，反對 3,108 票，棄權 4,077 票。
- 批准 2025 年度董事薪酬報告：贊成 48,251,875 票，反對 66,518 票，棄權 4,404,018 票。
- 批准公司組織章程細則第 159 條的應用，有效期至下次股東大會：贊成 48,307,317 票，反對 9,333 票，棄權 4,405,761 票。
所有決議均獲股東支持通過。是次 AGM 結果反映股東對現有管理層及審計安排的信心。投資者應留意董事會組成及薪酬政策獲確認，有助維持公司管治穩定性。公司短期內未有重大業務變動披露，但股東投票結果可視為對管理層策略的間接背書。
展開英文正文
8-K truefalse0001479615X000-00000000001479615us-gaap:CommonStockMember2026-06-162026-06-1600014796152026-06-162026-06-160001479615dei:AdrMember2026-06-162026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2026 Silence Therapeutics plc (Exact name of Registrant as Specified in Its Charter) England and Wales 001-39487 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 12 Hammersmith Grove London United Kingdom W6 7AP (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: +44 20 3457 6900 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share SLN The Nasdaq Stock Market LLC Ordinary share, nominal value £0.05 per share* * The Nasdaq Stock Market LLC * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. On June 16, 2026, Silence Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the nine resolutions set forth below, each of which was voted on and duly passed on a poll at the AGM. Each Resolution is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution. Ordinary Resolutions Resolution 1: To re-appoint as a director of the Company Rhonda Hellums. The votes were cast as follows: For Against Abstain 47,160,731 5,557,090 4,680 Resolution 2: To re-appoint as a director of the Company James Ede-Golightly. The votes were cast as follows: For Against Abstain 52,112,045 605,683 4,680 Resolution 3: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 48,234,208 73,667 4,414,536 Resolution 4: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119 Resolution 5: To re-appoint PricewaterhouseCoopers LLP as the Company’s U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119 Resolution 6: To authorize the Audit & Risk Committee to determine the U.K. statutory auditors’ remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,714,237 6,155 1,869 Resolution 7: To receive and adopt the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 52,715,076 3,108 4,077 Resolution 8: To approve the directors’ remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. The votes were cast as follows: For Against Abstain 48,251,875 66,518 4,404,018 Resolution 9: To approve the application of Article 159 of the Company’s articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. The votes were cast as follows: For Against Abstain 48,307,317 9,333 4,405,761 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Silence Therapeutics plc Date: June 16, 2026 By: /s/ Iain Ross Name: Iain Ross Title: Interim Principal Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)